Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Corteva Analysts Increase Their Forecasts After Upbeat Earnings

Published 02/02/2024, 18:34
Updated 02/02/2024, 19:40
© Reuters.  Corteva Analysts Increase Their Forecasts After Upbeat Earnings

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

Corteva, Inc. (NYSE: CTVA) reported better-than-expected fourth-quarter financial earnings, after the closing bell on Wednesday.

Corteva reported quarterly adjusted earnings of 15 cents per share, which beat the analyst estimates of 6 cents and representing a 6.25% decrease over earnings of 16 cents per share year-over-year. The company reported quarterly sales of $3.71 billion, representing a 3.08% decrease from sales of $3.83 billion year-over-year, according to data from Benzinga Pro.

The company sees 2024 net sales between $17.4 billion and $17.7 billion, versus the estimate of $17.608 billion. Adjusted earnings are anticipated to be between $2.70 and $2.90 per share, versus the $3.01 estimate.

Additionally, Corteva announced plans to repurchase approximately $1 billion shares in 2024.

“Corteva’s 2023 results reflect the execution of our value creation strategy, including its focus on productivity, differentiated product mix, and cost discipline. This, alongside a stand-out performance from our seed business, allowed us to deliver growth in earnings, cash and margin despite an ongoing imbalance in the global crop protection industry,” said Chuck Magro, Corteva CEO.

Corteva shares fell 1.1% to trade at $53.46 on Friday.

These analysts made changes to their price targets on Corteva after the company reported quarterly results.

  • Barclays raised the price target on Corteva from $50 to $55. Barclays analyst Benjamin Theurer maintained an Equal-Weight rating.
  • Wells Fargo increased Corteva price target from $54 to $65. Wells Fargo analyst Richard Garchitorena maintained an Overweight rating.
  • Keybanc boosted the price target on Corteva from $62 to $63. Keybanc analyst Aleksey Yefremov maintained an Overweight rating.
  • RBC Capital raised the price target on Corteva from $56 to $64. RBC Capital analyst Arun Viswanathan maintained an Outperform rating.
  • Oppenheimer increased the price target on Corteva from $60 to $62. Oppenheimer analyst Kristen Owen maintained an Outperform rating.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Now Read This: Dow Falls 150 Points; US Economy Adds 353,000 Jobs In January

Latest Ratings for CTVA

Feb 2022KeybancMaintainsOverweight
Nov 2021Morgan StanleyMaintainsOverweight
Nov 2021KeybancMaintainsOverweight

View the Latest Analyst Ratings

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.